Trader logo

Trxade Group, Inc. (NASDAQ: MEDS) to Present at LD Micro’s LD 500 Virtual Conference

The exclusively online LD 500 event is expected to gather more than 300 companies and 20,000 attendees in early September

By InvestorBrandNetworkPublished 4 years ago 4 min read
Like
  • Trxade reported record revenue in Q2 2020 and expects a strong second half of the year
  • If telemedicine services maintain popularity, market analysts project a seven-fold increase for the industry by 2025

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, will present at the virtual LD 500 in early September to an expected online audience of more than 20,000.The event is organized by LD Micro, an independent resource to the microcap world, which started off as a newsletter highlighting unique companies and has transformed into the pre-eminent event platform in the space.

The upcoming LD 500, taking place September 1st-4th, 2020, is the company’s most ambitious project yet, and the first event that can be accessed by anyone. It is expected to feature over 300 companies and more than 20,000 attendees, according to LD Micro President Chris Lahiji.

“For the first time in ten years, we were unable to host our mid-year conference, which caused us to dream up the LD 500,” stated Lahiji. “While the economy and financial world have been turned upside down, investor interest is as high as we have ever seen, and we will have something for everyone.”

This news comes on the heels of Trxade Group reporting record revenues for the second quarter of 2020 and projections for a strong second half of the year. According to a company announcement, revenues increased 244% to a record $6.6 million, compared to revenue of $1.9 million in the same quarter last year. Second quarter revenue was up 199% when compared to revenues of $2.2 million in the first quarter of 2020 (http://nnw.fm/IfYds).

“As we move through the second half of 2020, we are better positioned than ever to execute upon our vision of continued growth of the platform, driven by new independent pharmacies, new suppliers and distributors,” Chairman and Chief Executive Officer Suren Ajjarapu said.

The revenue surge was primarily due to a significant increase in personal protective equipment (“PPE”) sales by the company’s Integra Pharma segment in response to the COVID-19 pandemic.

During the COVID-19 crisis, telehealth services have rapidly expanded. As a result, the company has been working to raise awareness of its supply chain trading platform that includes medical consultation and prescription drug solutions. As the spread of the novel coronavirus unexpectedly reached pandemic proportions and triggered the need for infection-fighting policies, Trxade Group has developed measures to help patients and providers continue to access resources through a virtual environment that is safe from contagion.

If telemedicine services maintain popularity with patients, and insurance providers continue to be responsive to reimbursing telehealth claims, market analysts at McKinsey & Company forecast a $250 billion telehealth market (http://nnw.fm/zYUhR) while Frost & Sullivan projects a seven-fold increase in telehealth by 2025 (http://nnw.fm/eEivE).

Headquartered in Tampa, Florida, Trxade Group, Inc. is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. The company operates across all 50 states with the central mission of making healthcare services affordable and accessible.

Trxade operates via four synergistic platforms: (1) B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, the company’s virtual wholesale division; (3) Bonum Health which offers affordable telehealth services; and (4) the DelivMeds app, a nationwide mail order delivery distribution network for independent pharmacies.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)

New York, New York

www.NetworkNewsWire.com

212.418.1217 Office

[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.

investing
Like

About the Creator

InvestorBrandNetwork

The InvestorBrandNetwork (IBN) is comprised of 40+ investor focused brands and offers a comprehensive suite of corporate communications solutions that reach new audiences on an ongoing focus basis. Full disclaimers: http://bit.ly/2S7w1sC

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2024 Creatd, Inc. All Rights Reserved.